Pharmacologic Treatment of Symptomatic Hypertrophic Cardiomyopathy

Diagnosis and Management of Hypertrophic Cardiomyopathy

Volumn , Issue , 2007, Pages 200-219

  Sherrid, Mark V ^a   Barac, Ivan ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

Intramural coronary; Myofiber disarray; Nonatherosclerotic; Perivascular fibrosis; Symptomatic hypertrophic cardiomyopathy

Indexed keywords

EID: 17144414342     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987469.ch14     Document Type: Chapter

References (74)

1. Maron BJ. Hypertrophic cardiomyopathy: A systematic review. JAMA 2002; 287: 130820.
2. Wigle ED, Rakowski H, Kimball BP, William WG. Hypertrophic cardiomyopathy - clinical spectrum and treatment. Circulation 1995; 92: 1680-92.
3. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardio-myopathy. N Engl J Med 1997; 336: 775-85.
4. Jiang L, Levine RA, King ME, Weyman AE. An integrated mechanism for SAM of the mitral valve in hypertrophic cardiomyopathy based on echocardiographic observations. Am Heart J 1987; 113: 633-44.
5. Sherrid MV, Chu CK, DeLia E, Mogtader A, Dwyer Jr. EM. An echocardiographic study of the fluid mechanics of obstruction in hypertrophic cardiomyopathy. J Am Coll Cardiol 1993; 22: 816-25.
6. Sherrid MV, Pearle G, Gunsburg D. The mechanism of negative inotropes in obstructive hypertrophic cardiomyopathy. Circulation 1998; 97: 41-7.
7. Sherrid M, Gunsburg DZ, Moldenhauer S, Pearle G. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2000; 36: 1344-54.
8. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 2000; 5: 36-44.
9. Bonow RO. Left ventricular diastolic function in hypertrophic cardiomyopathy. Herz 1991; 16: 13-21.
10. Lele SS, Thomson HL, Seo H, Belenkie I, McKenna WJ, Frenneaux MP. Exercise capacity in hypertrophic cardiomyopathy. Role of stroke volume limitation, heart rate and diastolic filling characteristics. Circulation 1995; 92: 2886-94.
11. Cannon RO, Rosing DR, Maron BJ. Myocardial ischemia in patients with hypertrophic cardiomyopathy: Contribution of inadequate vasodilator reserve and elevated left ven-tricular filling pressures. Circulation 1985; 71: 234-43.
12. Dilsiziam V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1993; 22: 796-80.
13. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural ('small vessel') coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986; 8: 545-57.
14. Petkow DP, Krzanowski M, Nizankowski R, Szczeklik A, Dubiel JS. Effect of verapamil on systolic and diastolic coronary blood flow velocity in asymptomatic and mildly symptomatic patients with hypertrophic cardiomyopathy. Heart 2000; 83: 262-6.
15. Udelson JE, Bonow RO, O'Gara PT et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1989; 79: 1052-60.
16. Gwathmey JK, Warren SE, Briggs GM et al. Diastolic dysfunction in hypertrophic cardio-myopathy. Effect on active force generation during systole. J Clin Invest 1991; 87: 1023-31.
17. Lubic SP, Giacomini KM, Giacomini JC. The effects of modulation of calcium influx through the voltage-sensitive calcium channel on cardiomyocyte hypertrophy. J Mol Cell Cardiol 1995; 27: 917-25.
18. Kaltenbach M, Hopf R, Kober G, Bussmann WD, Keller M, Petersen Y. Treatment of hy-pertrophic obstructive cardiomyopathy with verapamil. Br Heart J 1979; 42: 35-42.
19. Rosing DR, Kent KM, Borer JS, Seides SF, Maron BJ, Epstein SE. Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. Circulation 1979; 60: 1201-7.
20. Hanrath P, Schluter M, Sonntag F, Diemert J, Bleifeld W. Influence of verapamil therapy on left ventricular performance at rest and during exercise in hypertrophic cardiomyopathy. Am J Cardiol 1983; 52: 544-8.
21. Bonow RO, Dilsizian V, Rosing DR, Maron BJ, Bacharach SL, Green MV. Verapamil-in-duced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: Short- and long-term effects. Circulation 1985; 72: 853-64.
22. Rosing DR, Kent KM, Maron BJ, Epstein SE. Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. Circulation 1979; 60: 1208-13.
23. Rosing DR, Condit JR, Maron BJ et al. Verapamil therapy: A new approach to the pharma-cologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration. Am J Cardiol 1981; 48: 545-53.
24. Rosing DR, Idanpaan-Heikkila U, Maron BJ, Bonow RO, Epstein SE. Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy. Am J Cardiol 1985; 55: 185B-195B.
25. Gilligan DM, Chan WL, Joshi J et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol 1993; 21: 1672-9.
26. Bonow RO, Rosing DR, Epstein SE. The acute and chronic effects of verapamil on left ventricular function in patients with hypertrophic cardiomyopathy. Eur Heart J 1983; 4 (Suppl. F): 57-65.
27. Bonow RO, Vitale DF, Maron BJ, Bacharach SL, Frederick TM, Green MV. Regional left ventricular asynchrony and impaired global left ventricular filling in hypertrophic car-diomyopathy: Effect of verapamil. J Am Coll Cardiol 1987; 9: 1108-16.
28. Hartmann A, Schnell J, Hopf R, Kneissl G. Persisting effect of Ca(2+)-channel blockers on left ventricular function in hypertrophic cardiomyopathy after 14 years' treatment. Angiology 1996; 47: 765-73.
29. Hopf R, Kaltenbach M. Ten year results and survival of patients with hypertrophic car-diomyopathy treated with calcium antagonists. Z Kardiol 1987; 76: 137-44.
30. Spicer RL, Rocchini AP, Crowley DC, Rosenthal A. Chronic verapamil therapy in pediatric and young adult patients with hypertrophic cardiomyopathy. Am J Cardiol 1984; 53: 1614-9.
31. Gregor P, Widimsky P, Cervenka V, Visek V, Sladkova T, Dvorak J. Use of verapamil in the treatment of hypertrophic cardiomyopathy. Cor Vasa 1986; 28: 404-12.
32. Tendera M, Polonski L, Kozielska E. Left ventricular end-diastolic pressure-volume re-lationships in hypertrophic cardiomyopathy. Changes induced by verapamil. Chest 1983; 84: 54-7.
33. Kass DA, Wolff MR, Ting CT et al. Diastolic compliance of hypertrophied ventricle is not acutely altered by pharmacologic agents influencing active processes. Ann Intern Med 1993; 119: 466-73.
34. Hess OM, Grimm J, Krayenbuehl HP. Diastolic function in hypertrophic cardiomyopathy: Effects of propranolol and verapamil on diastolic stiffness. Eur Heart J 1983; 4: 47-56.
35. TenCate FJ, Serruys PW, Mey S, Roelandt J. Effects of short-term administration of verapamil on left ventricular relaxation and filling dynamics measured by a combined hemodynamic-ultrasonic technique in patients with hypertrophic cardiomyopathy. Cir-culation 1983; 68: 1274-9.
36. Tendera M, Schneeweiss A, Bartoszewski A, Polonski L, Wodniecki J, Salamon A. The acute response of left ventricular filling dynamics to intravenous verapamil predicts the changes in exercise tolerance after oral verapamil therapy in patients with hypertrophic cardiomyopathy. Eur Heart J 1993; 14: 410-15.
37. Bonow RO, Ostrow HG, Rosing DR et al. Effects of verapamil on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy: Pressure-volume analysis with a nonimaging scintillation probe. Circulation 1983; 68: 1062-73.
38. Taniguchi Y, Sugihara H, Ohtsuki K et al. Effect of verapamil on myocardial ischemia in patients with hypertrophic cardiomyopathy: Evaluation by exercise thallium-201 SPECT. J Cardiol 1994; 24: 45-51.
39. Dimitrow PP, Krzanowski M, Grodecki J et al. Verapamil improves the pacing-induced vasodilatation in symptomatic patients with hypertrophic cardiomyopathy. Int J Cardiol 2002; 83: 239-47.
40. Curtius JM, Stoecker J, Loesse B, Welslau R, Scholz D. Changes of the degree of hypertro-phy in hypertrophic obstructive cardiomyopathy under medical and surgical treatment. Cardiology 1989; 76: 255-63.
41. Kunkel B, Schneider M, Eisenmenger A, Bergmann B, Hopf R, Kaltenbach M. Myocardial biopsy in patients with hypertrophic cardiomyopathy: Correlations between morphologic and clinical parameters and development of myocardial hypertrophy under medical therapy. Z Kardiol 1987; 76: 33-8.
42. Hopf R, Thomas J, Klepzig H, Kaltenbach M. Treatment of hypertrophic cardiomyopathy with nifedipine and propranolol in combination. Z Kardiol 1987; 76: 469-78.
43. Betocchi S, Piscione F, Losi MA et al. Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy. Am J Cardiol 1996; 78: 451-7.
44. Pollick C. Muscular subaortic stenosis: Hemodynamic and clinical improvement after disopyramide. N Engl J Med 1982; 307: 997-9.
45. Pollick C, Kimball B, Henderson M, Wigle ED. Disopyramide in hypertrophic cardiomy-opathy. I. Hemodynamic assessment after intravenous administration. Am J Cardiol 1988; 62: 1248-51.
46. Matsubara H, Nakatani S, Nagata S et al. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1995; 26: 768-75.
47. Wigle D, Sasson Z, Henderson MA et al. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Progr Cardiovasc Dis 1985; 28: 1-83.
48. Maron MS, Olivotto I, Betocchi S et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348: 295-303.
49. Sherrid MV, Gunsburg DZ, Pearle G. Midsystolic drop in left ventricular ejection velocity in obstructive hypertrophic cardiomyopathy. The lobster claw abnormality. J Am Soc Echocardiogr 1997; 10: 707-12.
50. Harrison DC, Braunwald E, Glick G, Mason DT, Chidsey CA, Ross J Jr. Effects of beta ad-renergic blockade on the circulation with particular reference to observations in patients with hypertrophic subaortic stenosis. Circulation 1964; 29: 84-98.
51. Goodwin JF, Shah PM, Oakley CM, Cohen J, Yipintsoi T, Pocock W. The clinical pharma-cology of hypertrophic obstructive cardiomyopathy. In: Wolstenholme GEW, O'Conner M, eds. Cardiomyopathies. Boston, MA: Little Brown, 1964: 189-213.
52. Sharma S, Elliott P, Whyte G et al. Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. Am J Cardiol 2000; 86: 162-8.
53. Ostman-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: Improved survival following high-dose beta-adrenoceptor antagonist treatment. J Am Coll Cardiol 1999; 34: 1813-22.
54. Sherrid MV, Barac I, Maron B et al. A multicenter study of the safety and efficacy of diso-pyramide for treating symptomatic obstructive hypertrophic cardiomyopathy [abstract]. J Am Coll Cardiol 2003; (Suppl. A): 170A.
55. McKenna WJ, Behr ER. Hypertrophic cardiomyopathy: Management, risk stratification, and prevention of sudden death. Heart 2002; 87: 169-76.
56. Epstein SE, Rosing DR. Verapamil: Its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation 1981; 64: 437-41.
57. Lorell BH. Use of calcium channel blockers in hypertrophic cardiomyopathy. Am J Med 1985; 78: 45-54.
58. Sherrid M, Delia E, Dwyer E. Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 1988; 62: 1085-8.
59. Pollick C. Disopyramide in hypertrophic cardiomyopathy. Noninvasive assessment after oral administration. Am J Cardiol 1988; 62: 1252-5.
60. Kimball BP, Bui S, Wigle ED. Acute dose-response effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy. Am Heart J 1995; 125: 1691-7.
61. Cokkinos DV, Salpeas D, Ioannou NE, Christoulas S. Combination of disopyramide and propranolol in hypertrophic cardiomyopathy. Can J Cardiol 1989; 5: 33-6.
62. Hongo M, Nakatsuka T, Takenaka H et al. Effects of intravenous disopyramide on coronary hemodynamics and vasodilator reserve in hypertrophic obstructive cardiomyopathy. Cardiology 1996; 87: 6-11.
63. Duncan WJ, Tyrrell MJ, Bharadwaj BB. Disopyramide as a negative inotrope in obstructive cardiomyopathy in children. Can J Cardiol 1991; 7: 81-6.
64. Niki K, Sugawara M, Asano R et al. Disopyramide improves the balance between myo-cardial oxygen supply and demand in patients with hypertrophic obstructive cardiomy-opathy. Heart Vessels 1997; 12: 111-18.
65. Pollick C, Giacomini KM, Blaschke TF et al. The cardiac effects of d- and l-disopyramide in normal subjects: A noninvasive study. Circulation 1982; 66: 447-53.
66. Sakai Y, Sekiya S, Inazu M, Homma I, Honda H, Irino O. Evidence that the Na+-Ca2+ exchange system is related to the antiarrhythmic action of disopyramide. Gen Pharmacol 1989; 20: 105-9.
67. Ragosta M, Weihl AC, Rosenfeld LE. Potentially fatal interaction between erythromycin and disopyramide. Am J Med 1989; 86: 465-6.
68. Kober G, Hopf R, Biamino G et al. Long-term treatment of hypertrophic cardiomyopathy with verapamil or propranolol in matched pairs of patients: Results of a multicenter study. Z Kardiol 1987; 76: 113-18.
69. Hamada M, Shigematsu Y, Ikeda S et al. Class Ia antiarrhythmic drug cibenzoline: A new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1997; 96: 1520-4.
70. Tokudome T, Mizushige K, Ueda T, Sakamoto S, Matsuo H. Effect of disopyramide on left ventricular pressure gradient in hypertrophic obstructive cardiomyopathy in comparison with propranolol - a case report. Angiology 1999; 50: 331-5.
71. Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med 1985; 312: 277-83.
72. Sussman MA, Lim HW, Gude N et al. Prevention of cardiac hypertrophy in mice by calci- neurin inhibition. Science 1998; 281: 1690-3.
73. Lim DS, Lutucuta S, Bachireddy P et al. Angiotensin II blockade reverses myocardial fi-brosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001; 103: 789-91.
74. Patel R, Nagueh SF, Tsybouleva N et al. Simvastatin induces regression of cardiac hyper-trophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001; 104: 317-24.